Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -45.18% is 77% above its 5-year average of -195.56%, near the high end of its 5-year range (-391.61%–-45.18%).
63.81% above its 12-month average of -124.83%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -14.71%.
RETURN ON ASSETS (ROA)
-45.18%
RETURN ON ASSETS (ROA) AVG TTM
-124.83%
RETURN ON ASSETS (ROA) AVG 3Y
-176.38%
RETURN ON ASSETS (ROA) AVG 5Y
-195.56%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+63.81%
CURRENT VS 3Y AVG
+74.39%
CURRENT VS 5Y AVG
+76.90%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-40.14%
vs the sector median at left
TriSalus Life Sciences, Inc.
Market Cap
$270.31M
Return on Assets (ROA)
-45.18%
TTM Avg
-124.83%
3Y Avg
-176.38%
5Y Avg
-195.56%
Market Cap
$269.97M
Return on Assets (ROA)
-5.36%
TTM Avg
-34.75%
3Y Avg
-39.14%
5Y Avg
-23.69%
Market Cap
$269.95M
Return on Assets (ROA)
-66.64%
TTM Avg
-23.99%
3Y Avg
-11.65%
5Y Avg
-6.11%
Market Cap
$270.89M
Return on Assets (ROA)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$271.00M
Return on Assets (ROA)
-48.44%
TTM Avg
-42.51%
3Y Avg
-39.18%
5Y Avg
-34.60%
Market Cap
$267.20M
Return on Assets (ROA)
-37.07%
TTM Avg
-27.27%
3Y Avg
-64.53%
5Y Avg
-52.03%
Market Cap
$273.53M
Return on Assets (ROA)
-4.08%
TTM Avg
-58.27%
3Y Avg
-50.03%
5Y Avg
-43.16%
Market Cap
$265.98M
Return on Assets (ROA)
-32.87%
TTM Avg
-28.32%
3Y Avg
-25.80%
5Y Avg
-21.10%
Market Cap
$264.16M
Return on Assets (ROA)
-35.96%
TTM Avg
-58.88%
3Y Avg
-82.10%
5Y Avg
-113.46%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| TriSalus Life Sciences, Inc. (TLSI) | $270.31M | -45.18% | -124.83% | -176.38% | -195.56% |
| SAB Biotherapeutics, Inc. (SABS)vs › | $269.97M | -5.36% | -34.75% | -39.14% | -23.69% |
| Vanda Pharmaceuticals Inc. (VNDA)vs › | $269.95M | -66.64% | -23.99% | -11.65% | -6.11% |
| Scribe Therapeutics Inc. (SCTX)vs › | $270.89M | N/A | N/A | N/A | N/A |
| Fate Therapeutics, Inc. (FATE)vs › | $271.00M | -48.44% | -42.51% | -39.18% | -34.60% |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $267.20M | -37.07% | -27.27% | -64.53% | -52.03% |
| Rocket Pharmaceuticals, Inc. (RCKT)vs › | $273.53M | -4.08% | -58.27% | -50.03% | -43.16% |
| Treace Medical Concepts, Inc. (TMCI)vs › | $265.98M | -32.87% | -28.32% | -25.80% | -21.10% |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $264.16M | -35.96% | -58.88% | -82.10% | -113.46% |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $263.83M | -34.24% | -52.06% | -53.17% | -44.53% |
ROA
-45.2%
ROE
-430.7%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -111.03% |
| 2024-12-31 | -138.64% |
| 2023-12-31 | -241.33% |
| 2022-12-31 | -214.54% |
| 2021-12-31 | -76.23% |
| 2020-12-31 | -391.61% |
